title: Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of the 5-HT3 receptor antagonists.
abstract: The roles of hippocampus (HP) and the nucleus accumbens septi (NAS) in the anxiolytic activity of two 5-HT3 receptor antagonists were studied in two animal models of anxiety, in rats. Injection of tropisetron (0.005 and 0.01 microgram) or ondansetron (1.0 and 2.5 micrograms) into the hippocampus increased punished consumption of water in the Vogel conflict test. In the open field test neither 5-HT3 receptor antagonists had anxiolytic-like effects. Tropisetron (0.01 and 0.025 microgram) injected into the NAS caused a marked increase in punished drinking, while ondansetron (0.01-15.0 micrograms) had no effect. In the open field test, tropisetron (0.001, 0.005 and 0.01 microgram) and ondansetron (1.0 and 2.5 micrograms) given to the NAS increased the number of entries into the central part of the open-field, and the time spent in the central sector of the arena. Depletion of 5-HT significantly enhanced the anxiolytic-like effect of intra-NAS-injected tropisetron in the open field, at the dose of 0.005 microgram. Moreover, 5,7-DHT lesions produced a tendency to increase motor activity in tropisetron-treated rats. Both hippocampal and accumbens 5-HT3 receptors seem to contribute to the anxiolytic-like effects of 5-HT3 antagonists in the Vogel test. It also appears that this effect of 5-HT3 receptor antagonists is related to their action on postsynaptic 5-HT3 receptors within the NAS, and depends on the functional state of the 5-HT innervation ascending from the raphe nuclei. Thus, the present data add more arguments for the more specific involvement of this limbic nucleus in emotional control.
authors.affiliation: Department of Pharmacology and Physiology of the Nervous System, Institute of Psychiatry and Neurology, Warsaw, Poland.
authors.forename: R
authors.initials: R
authors.lastname: Stefański
authors.forename: W
authors.initials: W
authors.lastname: Pałejko
authors.forename: A
authors.initials: A
authors.lastname: Bidziński
authors.forename: W
authors.initials: W
authors.lastname: Kostowski
authors.forename: A
authors.initials: A
authors.lastname: Płaźnik
mesh_terms: D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D003220:Conflict, Psychological; D004327:Drinking Behavior / Q000187:drug effects; D004597:Electroshock; D006624:Hippocampus / Q000502:physiology*; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D008845:Microinjections; D009714:Nucleus Accumbens / Q000502:physiology*; D017294:Ondansetron / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000502:physiology*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D000077526:Tropisetron
chemical_list: D014151:Anti-Anxiety Agents; D007211:Indoles; D012702:Serotonin Antagonists; D015116:5,7-Dihydroxytryptamine; D012701:Serotonin; D017294:Ondansetron; D000077526:Tropisetron